Monday, July 25, 2022 Daily Archives

eBook: Factors Affecting Scalability of Cell Therapies

The number of cell and gene therapies in different phases of development is increasing. The industry currently needs to increase commercial good manufacturing practice (GMP) capacity to keep up with current and future demands. Cell and gene therapy scale-up from clinical to commercial capacity levels can reduce cost of goods and thus price per dose.  An optimized bioprocess facilitates scale-up from hundreds (clinical scale) to thousands of doses (commercial scale). Different approaches for increasing scale can be taken. For example,…

Pfizer forks out $470m to expand Pearl River vaccine plant

Pfizer is set to expand its vaccine research facilities in Pearl River, New York to keep ahead of the game in the mRNA space. Bloomberg reported that Pfizer will invest $470 million to construct a building and renovate existing facilities located on its campus in Pearl River, which is 25 miles northwest of New York. A spokesperson confirmed this to BioProcess Insider, adding the plant will focus on the firm’s messenger RNA (mRNA) portfolio. Pfizer anticipates completing the Pearl River…

Podcast: Lumen using spirulina to make ‘edible’ antibody drugs

We sit down with Lumen Biosciences CEO Brian Finrow to discuss how his company hopes to use its spirulina-based platform to develop drugs targeting gastrointestinal disorders. Lumen Biosciences is a biotech looking to unlock the full potential of biologic drugs, whose promise has been held back by the lack of scalable technology. The firm is developing ‘oral antibodies’ using its platform based on spirulina– the protein-rich cyanobacteria touted by many health enthusiasts as a ‘superfood’ – to create tiny factories…